TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10942231

Group type: EXPERIMENTAL
Intervention: ATRA followed by three courses of daunorubicin-AraC chemotherapy
Number of subjects: 101

Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: ATRA
Number of subjects: 101
Study: 8826020

Group type: EXPERIMENTAL
Intervention: 0.1% ropivacaine
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 0.2% ropivacaine
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 0.3% ropivacaine
Number of subjects: 24

Group type: COMPARATOR
Intervention: 0.25% bupivacaine
Number of subjects: 24

Group type: COMPARATOR
Intervention: Isotonic saline
Number of subjects: 24
Study: 1603224

Group type: EXPERIMENTAL
Intervention: Tranexamic acid (9 g a day)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 6141858

Group type: EXPERIMENTAL
Intervention: Almitrine 100 mg orally
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31213044

Group type: EXPERIMENTAL
Intervention: Ultrasonography (U) group
Number of subjects: 150

Group type: COMPARATOR
Intervention: Palpation (P) group
Number of subjects: 150
Study: 30103096

Group type: EXPERIMENTAL
Intervention: Nivolumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Docetaxel
Number of subjects: 0
Study: 26898748

Group type: COMPARATOR
Intervention: Intensive Behavior Therapy fee-for-service (FFS) model
Number of subjects: 1440

Group type: EXPERIMENTAL
Intervention: Patient-centered medical home (PCMH) model
Number of subjects: 1440

Group type: EXPERIMENTAL
Intervention: Centralized disease management (DM) model
Number of subjects: 1440
Study: 23761378

Group type: EXPERIMENTAL
Intervention: High-activity allele of MAOA uVNTR polymorphism in girls
Number of subjects: 1101

Group type: EXPERIMENTAL
Intervention: Experience of negative familial stressors
Number of subjects: 1101

Group type: EXPERIMENTAL
Intervention: Low stress level in girls with high-activity allele
Number of subjects: 1101

Group type: COMPARATOR
Intervention: Boys with MAOA uVNTR polymorphism
Number of subjects: 1101
Study: 22962858

Group type: EXPERIMENTAL
Intervention: Tailored print reminder
Number of subjects: 1859

Group type: COMPARATOR
Intervention: Non-tailored print reminder
Number of subjects: 1859
Study: 19679557

Group type: EXPERIMENTAL
Intervention: Mupirocin
Number of subjects: 2450
Study: 18622251

Group type: EXPERIMENTAL
Intervention: Amlodipine-based regimen (n = 12)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Lisinopril-based regimen (n = 13)
Number of subjects: 25
Study: 15913920

Group type: EXPERIMENTAL
Intervention: Desipramine (up to 300 mg per day)
Number of subjects: 111

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Desipramine
Number of subjects: 111
Study: 12101597

Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 100

Group type: COMPARATOR
Intervention: Antiepileptic drugs (Control)
Number of subjects: 100
Study: 9520056

Group type: EXPERIMENTAL
Intervention: Intratympanic dexamethasone
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (saline and sodium hyaluronate)
Number of subjects: 20
Study: 7977124

Group type: EXPERIMENTAL
Intervention: Integrated backscatter imaging in patients with nonrestrictive ventricular septal defect
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Histologic analysis of myocardial tissue in patients
Number of subjects: 16
Study: 2574732

Group type: EXPERIMENTAL
Intervention: Formoterol 12 micrograms
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Formoterol 24 micrograms
Number of subjects: 16

Group type: COMPARATOR
Intervention: Salbutamol 200 micrograms
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 1095122

Group type: COMPARATOR
Intervention: Nafoxidine (reference compound)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: L-Dopa
Number of subjects: 76
Study: 30516871

Group type: EXPERIMENTAL
Intervention: Cognitive therapy (CT)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Interpersonal psychotherapy (IPT)
Number of subjects: 85
Study: 29336881

Group type: EXPERIMENTAL
Intervention: Contracted endodontic cavities (CECs)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Traditional endodontic cavities (TECs)
Number of subjects: 30
Study: 26682780

Group type: EXPERIMENTAL
Intervention: Diet soft drink consumers
Number of subjects: 488

Group type: COMPARATOR
Intervention: Sugar-sweetened soft drink consumers
Number of subjects: 488

Group type: COMPARATOR
Intervention: Nonconsumers
Number of subjects: 488
Study: 24643427

Group type: EXPERIMENTAL
Intervention: ULLS + Exercise (BFR resistance training on KE three times per week during ULLS)
Number of subjects: 16

Group type: COMPARATOR
Intervention: ULLS (control group)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: ULLS + Exercise
Number of subjects: 16
Study: 22846643

Group type: EXPERIMENTAL
Intervention: High dose acupuncture (additional 4 needles at non‐acupoints bilaterally)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Low dose acupuncture (one needle at point Hegu bilaterally)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: High dose acupuncture
Number of subjects: 52

Group type: COMPARATOR
Intervention: Low dose acupuncture
Number of subjects: 52
Study: 19996308

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 30
Study: 18990229

Group type: EXPERIMENTAL
Intervention: Enzyme Replacement Therapy (ERT)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 27
Study: 15767357

Group type: EXPERIMENTAL
Intervention: Sunscreen applied using recommended application techniques
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Sunscreen reapplied after 3 hours
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control swabs (no sunscreen)
Number of subjects: 30
Study: 12387962

Group type: EXPERIMENTAL
Intervention: Chlorproguanil-dapsone
Number of subjects: 910

Group type: COMPARATOR
Intervention: Sulfadoxine-pyrimethamine
Number of subjects: 910
Study: 9698663

Group type: EXPERIMENTAL
Intervention: Orchidectomy (group 1, n = 217)
Number of subjects: 444

Group type: EXPERIMENTAL
Intervention: Parenteral polyoestradiol phosphate (PEP) 240 mg/month (group 2, n = 227)
Number of subjects: 444

Group type: COMPARATOR
Intervention: Comparison of cardiovascular complications between groups
Number of subjects: 444
Study: 7616460

Group type: EXPERIMENTAL
Intervention: Cognitive therapy (CT)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Attention/placebo group (APG)
Number of subjects: 30
Study: 2654335

Group type: EXPERIMENTAL
Intervention: Chemonucleolysis
Number of subjects: 151

Group type: COMPARATOR
Intervention: Open discectomy
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Open discectomy after chemonucleolysis
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Comparison of final results
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Both treatment groups
Number of subjects: 151
Study: 69058

Group type: EXPERIMENTAL
Intervention: 14-valent pneumococcal polysaccharide vaccine
Number of subjects: 11958
Study: 7137990

Group type: EXPERIMENTAL
Intervention: Aerosolized rimantadine HCl 25 mg in saline (10 min exposure twice daily)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Oral rimantadine HCl 50 mg (every 6 h, three times daily)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo (both aerosol and oral routes)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Aerosolized rimantadine and oral rimantadine
Number of subjects: 36
Study: 31389599

Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 210

Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 210
Study: 28299764

Group type: EXPERIMENTAL
Intervention: Bolus injection of furosemide (120 mg stat)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Infusion of furosemide (4 mg/minute)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Bolus injection and infusion of furosemide
Number of subjects: 50
Study: 27219099

Group type: EXPERIMENTAL
Intervention: Alcohol (0.8 g/kg) administered before viewing images (encoding condition)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Alcohol (0.8 g/kg) administered immediately after viewing images (consolidation condition)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo administered both before and after viewing images (control condition)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Alcohol (0.8 g/kg) in encoding condition with greater alcohol-induced stimulation
Number of subjects: 59
Study: 23723317

Group type: EXPERIMENTAL
Intervention: Rituximab retreatment at 1000 mg×1 (Arm A)
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Rituximab retreatment at 1000 mg×2 (Arm B)
Number of subjects: 143
Study: 22371301

Group type: EXPERIMENTAL
Intervention: Propranolol (40 mg)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 19437182

Group type: EXPERIMENTAL
Intervention: Wearing a pedometer
Number of subjects: 102

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 102
Study: 17689948

Group type: EXPERIMENTAL
Intervention: Continuous training (C), n=22, 80% of pre-training peak work rate
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Interval training (I), n=17, 30 min cycling (2 min at 90% peak work rate, 1 min at 50% peak work rate, bracketed by 7.5 min at 50% peak work rate)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Self-paced training (S), n=32, instructed to cycle, climb stairs and walk at home
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Continuous training (C) and Interval training (I)
Number of subjects: 71

Group type: COMPARATOR
Intervention: All groups (C, I, S)
Number of subjects: 71
Study: 15650985

Group type: EXPERIMENTAL
Intervention: Oxycodone 0.5 mg/kg/h
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Oxycodone 1.0 mg/kg/h
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Oxycodone 0.5 mg/kg/h and 1.0 mg/kg/h
Number of subjects: 20
Study: 11205921

Group type: EXPERIMENTAL
Intervention: Caspase-3 activity in T cells
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: T-cell apoptosis
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: TCR-zeta molecule expression
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: IFN-gamma production
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Tumor necrosis factor alpha production
Number of subjects: 22
Study: 9698139

Group type: EXPERIMENTAL
Intervention: Tooth count tertiles (extreme groups)
Number of subjects: 1365

Group type: COMPARATOR
Intervention: WHO criteria for BMD
Number of subjects: 1365
Study: 7992446

Group type: EXPERIMENTAL
Intervention: 4200 kJ/day diet with combined aerobic and anaerobic exercise
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: 4200 kJ/day diet
Number of subjects: 121

Group type: COMPARATOR
Intervention: controls (no intervention)
Number of subjects: 121
Study: 2648188

Group type: EXPERIMENTAL
Intervention: 1.6 g/kg protein diet
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: 0.8 g/kg diet with protein evenly distributed between meals
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: 0.8 g/kg diet with protein restricted to the evening meal
Number of subjects: 5
Study: 10697473

Group type: EXPERIMENTAL
Intervention: Tricalcium phosphate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Calcium hydroxide
Number of subjects: 0
Study: 31898804

Group type: EXPERIMENTAL
Intervention: Computer-based navigation
Number of subjects: 12

Group type: COMPARATOR
Intervention: Conventional fluoroscopy
Number of subjects: 12
Study: 30794334

Group type: EXPERIMENTAL
Intervention: Budesonide with probiotic supplements (BP)
Number of subjects: 152

Group type: COMPARATOR
Intervention: Budesonide with placebo (B)
Number of subjects: 152
Study: 29029260

Group type: EXPERIMENTAL
Intervention: RSV postfusion F protein vaccine (120 µg) with glucopyranosyl lipid adjuvant (5 µg)
Number of subjects: 1894

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1894

Group type: EXPERIMENTAL
Intervention: RSV postfusion F protein vaccine
Number of subjects: 1894
Study: 25599284

Group type: EXPERIMENTAL
Intervention: TDF 300 mg plus optimized background regimen (OBR)
Number of subjects: 81
Study: 23568514

Group type: EXPERIMENTAL
Intervention: Standardized hypnotherapeutic‐behavioral treatment (n = 20)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Waiting list condition (n = 18)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Health-related quality of life (both groups)
Number of subjects: 38
Study: 20617889

Group type: EXPERIMENTAL
Intervention: Repetitive transcranial magnetic stimulation (rTMS) to the posterior superior temporal gyrus (pSTG)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Repetitive transcranial magnetic stimulation (rTMS) to the middle temporal gyrus (MTG)
Number of subjects: 0
Study: 19168857

Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 120
Study: 17085348

Group type: EXPERIMENTAL
Intervention: Needle-knife cut
Number of subjects: 91

Group type: COMPARATOR
Intervention: Persistent cannulation by standard techniques
Number of subjects: 91
Study: 15339772

Group type: EXPERIMENTAL
Intervention: Misoprostol (25-microg intravaginal dose)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study: 10513186

Group type: EXPERIMENTAL
Intervention: LA with 2 ml of 1% lidocaine using a 24‐gauge needle
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: LA with 0.5 ml of 1% lidocaine using a 27‐gauge needle
Number of subjects: 60

Group type: COMPARATOR
Intervention: Without LA
Number of subjects: 60
Study: 8655712

Group type: EXPERIMENTAL
Intervention: Nested PCR
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Immunohistochemistry
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Combination of nested PCR and immunohistochemistry
Number of subjects: 31
Study: 1517929

Group type: EXPERIMENTAL
Intervention: Prednisone therapy for 12 weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo dosing for 12 weeks
Number of subjects: 20
Study: 6391140

Group type: EXPERIMENTAL
Intervention: VAP (vindesine, doxorubicin, and cisplatin)
Number of subjects: 105

Group type: COMPARATOR
Intervention: VAP + thymosin
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Thymosin treatment
Number of subjects: 105
Study: 30690825

Group type: EXPERIMENTAL
Intervention: Lung ultrasound (LUS) integrated with clinical assessment
Number of subjects: 518

Group type: COMPARATOR
Intervention: Chest radiography (CXR) and N-terminal pro-B-type natriuretic peptide (NT-proBNP) integrated with clinical evaluation
Number of subjects: 518
Study: 28756402

Group type: EXPERIMENTAL
Intervention: Structured unsupervised home-based pulmonary rehabilitation programme
Number of subjects: 287

Group type: COMPARATOR
Intervention: Centre-based supervised pulmonary rehabilitation
Number of subjects: 287
Study: 27256936

Group type: EXPERIMENTAL
Intervention: Drug Adherence Enhancement Program
Number of subjects: 56

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 56
Study: 23877730

Group type: EXPERIMENTAL
Intervention: Endoscopic technique
Number of subjects: 60

Group type: COMPARATOR
Intervention: Minimal invasive open technique
Number of subjects: 60
Study: 22031518

Group type: EXPERIMENTAL
Intervention: Hyperinsulinemic‐normoglycemic clamp technique with 24‐h preoperative carbohydrate load
Number of subjects: 30

Group type: COMPARATOR
Intervention: Standard glucose control through insulin sliding scale treatment
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Hyperinsulinemic‐normoglycemic clamp technique
Number of subjects: 30
Study: 20141812

Group type: EXPERIMENTAL
Intervention: IPS e.max Press
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Procera AllCeram
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Metal ceramic (Simidur S 2 veneered with IPS Classic Porcelain)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (Procera AllCeram)
Number of subjects: 48
Study: 19189517

Group type: EXPERIMENTAL
Intervention: Antismoking counseling by physicians
Number of subjects: 1267
Study: 15733643

Group type: EXPERIMENTAL
Intervention: High treatment expectancy
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Taking pain medication and poor functional status at baseline
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Leg pain and back pain at baseline
Number of subjects: 105
Study: 12660386

Group type: EXPERIMENTAL
Intervention: High-strength levorphanol (0.75 mg)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Low-strength levorphanol (0.15 mg)
Number of subjects: 81
Study: 10713745

Group type: EXPERIMENTAL
Intervention: High-fat (HF) pre-load meal (55% of ADER)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Low-fat (LF) pre-load meal (20% of ADER)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Serum insulin concentration before eating the test meal
Number of subjects: 12
Study: 8661977

Group type: EXPERIMENTAL
Intervention: Nasal salmon calcitonin (sCT) 50 IU
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Nasal salmon calcitonin (sCT) 100 IU
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Nasal salmon calcitonin (sCT) 200 IU
Number of subjects: 208

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Nasal salmon calcitonin (sCT) (all doses)
Number of subjects: 208
Study: 1796850

Group type: EXPERIMENTAL
Intervention: Intravesical BCG
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Oral BCG
Number of subjects: 84

Group type: COMPARATOR
Intervention: Control group (TUR-BT)
Number of subjects: 84
Study: 6581174

Group type: EXPERIMENTAL
Intervention: Tetracycline therapy (daily for 50 weeks)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 14
Study: 31102793

Group type: EXPERIMENTAL
Intervention: Game-based virtual reality phone application
Number of subjects: 86

Group type: COMPARATOR
Intervention: Control group (traditional education)
Number of subjects: 86
Study: 28575910

Group type: EXPERIMENTAL
Intervention: Oropharyngeal administration of colostrum (OAC)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sterile water (control)
Number of subjects: 30
Study: 27507112

Group type: EXPERIMENTAL
Intervention: New or persistent hypochloremia at day 14
Number of subjects: 1960

Group type: EXPERIMENTAL
Intervention: Baseline hypochloremia that resolved by day 14
Number of subjects: 1960

Group type: EXPERIMENTAL
Intervention: Chloride measured at day 14
Number of subjects: 1960

Group type: EXPERIMENTAL
Intervention: Low baseline chloride
Number of subjects: 1960
Study: 24850938

Group type: EXPERIMENTAL
Intervention: Online simulated-patient case (virtual-patient group)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Faculty‐led problem‐based learning (PBL group)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned, but implied as the PBL group)
Number of subjects: 0
Study: 22880805

Group type: EXPERIMENTAL
Intervention: 1 g of cefazolin sodium intravenously 1 h prior to catheter insertion
Number of subjects: 60

Group type: COMPARATOR
Intervention: Saline intravenously 1 h prior to catheter insertion
Number of subjects: 60
Study: 20438307

Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 939

Group type: EXPERIMENTAL
Intervention: Losartan-based regimens
Number of subjects: 939
Study: 18978105

Group type: EXPERIMENTAL
Intervention: 10-microgram E2 vaginal tablets
Number of subjects: 309

Group type: COMPARATOR
Intervention: Placebo vaginal tablets
Number of subjects: 309
Study: 16085584

Group type: EXPERIMENTAL
Intervention: (99m)Tc‐tetrofosmin uptake after nitrate administration
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: (99m)Tc‐tetrofosmin perfusion defect severity after nitrate administration
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: ceMRI cutoff below 40%
Number of subjects: 21

Group type: COMPARATOR
Intervention: (99m)Tc‐tetrofosmin uptake at rest
Number of subjects: 21

Group type: COMPARATOR
Intervention: (99m)Tc‐tetrofosmin perfusion defect severity at rest
Number of subjects: 21
Study: 11910262

Group type: EXPERIMENTAL
Intervention: Paroxetine at 20 mg/day for 10 days
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Sertraline at 50 mg/day for 3 days, followed by 100 mg/day for 10 days
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Fluoxetine at 20 mg/day for 28 days
Number of subjects: 45
Study: 10327575

Group type: EXPERIMENTAL
Intervention: Glutamine substitution
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control (without glutamine)
Number of subjects: 34
Study: 8417217

Group type: EXPERIMENTAL
Intervention: Intralesional purified clostridial collagenase
Number of subjects: 49

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 49
Study: 3529911

Group type: EXPERIMENTAL
Intervention: Flecainide (up to 2 mg/kg intravenously and then orally)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Quinidine (up to 1.2 g orally)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Flecainide
Number of subjects: 60

Group type: COMPARATOR
Intervention: Quinidine
Number of subjects: 60
Study: 29294954

Group type: EXPERIMENTAL
Intervention: Home visiting program (Healthy Families Massachusetts)
Number of subjects: 448

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 448
Study: 31567611

Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA 40 U
Number of subjects: 865

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 865
Study: 30376747

Group type: EXPERIMENTAL
Intervention: High BMI / High NP
Number of subjects: 997

Group type: COMPARATOR
Intervention: Low BMI / Low NP
Number of subjects: 997

Group type: EXPERIMENTAL
Intervention: Higher NP levels
Number of subjects: 997

Group type: EXPERIMENTAL
Intervention: BMI around 25 kg/m2
Number of subjects: 997
Study: 26681715

Group type: EXPERIMENTAL
Intervention: LY2409021 10 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: LY2409021 30 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: LY2409021 60 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: LY2409021 2.5 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: LY2409021 20 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: LY2409021
Number of subjects: 0
Study: 26664304

Group type: EXPERIMENTAL
Intervention: Atorvastatin 160 mg loading dose followed by 80 mg daily
Number of subjects: 140

Group type: COMPARATOR
Intervention: Atorvastatin 20 mg daily
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 140
Study: 23749418

Group type: EXPERIMENTAL
Intervention: HIV-infected adults
Number of subjects: 0

Group type: COMPARATOR
Intervention: Matched uninfected control group
Number of subjects: 0